News

Dynavax Technologies: Hepatitis-B Vaccine Specialist Looking Good
Discover why Dynavax Technologies' stock dropped 25% despite HEPLISAV-B's growth & double-digit projections through 2030.
The Lancet1d
A 2024 global report on national policies, programmes, and progress towards hepatitis C elimination: findings from 33 hepatitis elimination profiles
The Coalition for Global Hepatitis Elimination's National Hepatitis Elimination Profiles assess the status of national data, ...